GALVANY PHARMA LIMITED

Active
Company number 13977261Private limited companyIncorporated 2022

Key figures

£2,772,355+60.8%
Net assets 2025
+10.9%
Average annual growth 2022–2025
01 m2 m3 m2022202320242025

Like most small UK companies, GALVANY PHARMA LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2025

Sector comparison

SIC 21100

Where the company stands among the 1,055 active companies whose first SIC code is 21100 (Manufacture of basic pharmaceutical products).

Net assets£2,772,355
Higher than 80% · median £40,799
Total assets£3,443,928
Higher than 73% · median £301,666
Cash£1,104,227
Higher than 77% · median £135,555
Employees3
Higher than 65% · median 1
Company age4.7 years
Younger than 68% · median 9.0 years

Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 1,055. The line on each bar marks the median.

Summary: GALVANY PHARMA LIMITED

What kind of company is it?

GALVANY PHARMA LIMITED is a private limited company registered with Companies House under company number 13977261. It was incorporated on 15 Mar 2022. Its status is active. The registered office is in Stevenage (SG1). Its nature of business (SIC 2007) is manufacture of basic pharmaceutical products (21100), manufacture of pharmaceutical preparations (21200), research and experimental development on biotechnology (72110).

How is the company doing financially?

The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files small company accounts (filleted). Net assets were £2,772,355, up 60.8% on the previous year. Cash at bank and in hand was £1,104,227. The company had an average of 3 employees. Figures are available for 4 financial years (2022–2025).

How does it compare with similar companies?

Compared with 1,055 active companies whose first SIC code is 21100: By net assets it ranks higher than 80% of them (median £40,799). By total assets it ranks higher than 73% of them (median £301,666). By cash it ranks higher than 77% of them (median £135,555). By number of employees it ranks higher than 65% of them (median 1). It is younger than 68% of them (median age 9.0 years).

Does it supply the public sector?

The company is named as a supplier in 7 public contract award notices from 2 public sector buyers since 2023. Its most frequent buyer is NHS England (6 contracts). 4 of the awards are shared with other suppliers, typically framework agreements.

What do public registers and reports show?

HMRC lists it as an importer of goods, mainly pharmaceuticals.

Who runs and controls the company?

The company has 3 current directors.

When are its next filings due?

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 20 Mar 2027.

Control structure

GALVANY DEVELOPMENTS LTD is the only person with significant control on record for this company; the PSC register shows no further links.

Filed accounts2022–2025
2022202320242025
Cash at bank and in hand982,043678,431390,3491,104,227
Total assets2,037,1031,987,9482,396,0133,443,928
Total liabilities————
Net assets / total equity2,031,8071,879,0341,724,1752,772,355
Average number of employees0033

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Public contracts

7 contracts

GALVANY PHARMA LIMITED is named as a supplier in 7 public contract award notices from 2 public sector buyers since 2023. 4 awards are shared with other suppliers.

Contracts per year
Main buyers2
NHS England
6 contracts
ATAMIS LTD
1 contract
Contracts
  1. NHS National Generic Pharmaceuticals - Wave 16a‡NHS England · shared by 101 suppliers, up to £414,358,050 in total · 2 lots · runs until Jan 2029
  2. NHS National Generic Pharmaceuticals - Wave 15c‡NHS England · shared by 104 suppliers, up to £403,702,000 in total · runs until May 2028
  3. NHS National Generic Pharmaceuticals Wave 15b‡NHS England · £1
  4. NHS National Generic Pharmaceuticals Wave 15a‡NHS England · £1
  5. NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 2)‡NHS England · shared by 63 suppliers, up to £1 in total · runs until May 2027
Show 2 more
  1. NHS National Generic Pharmaceuticals Wave 14c‡NHS England · £2 · 2 lots
  2. NHS National Generic Pharmaceuticals Wave 14b‡ATAMIS LTD · shared by 99 suppliers, up to £428,226,984 in total

From contract award notices on Contracts Finder (since 2016) and Find a Tender (since 2021), published by the Cabinet Office under the Open Government Licence v3.0. Values are as published by the buyer and usually cover the whole contract term; the total leaves out awards shared between several suppliers, where the published figure is a ceiling for all of them, placeholder values and single figures of £1 billion or more. Notices marked ‡ do not state a company number and were linked by an exact match on the registered name. Contracts below the publication thresholds and those of devolved buyers that publish elsewhere are not included.

Registers and licences

International trade‡

Listed by HMRC as an importer of goods in 7 of the last 12 months on record, most recently July 2026. Main goods: pharmaceuticals.

From HMRC's monthly lists of importers and exporters. Traders can ask to be left off the lists, so absence does not mean a company does not trade.

Sources: Charity Commission for England and Wales, Care Quality Commission, Home Office and HM Revenue & Customs, under the Open Government Licence v3.0. Entries marked ‡ come from lists that do not state a company number and were linked by an exact match on the registered name.

History

11 events
  1. Financial year 2025 endedAccounts: net assets £2.8m, 3 employees
  2. Financial year 2024 endedAccounts: net assets £1.7m, 3 employees
  3. Christopher Blair WAGSTAFF resignedDirector
  4. Financial year 2023 endedAccounts: net assets £1.9m, 0 employees
  5. Financial year 2022 endedAccounts: net assets £2m, 0 employees
  6. Tracey Evelyn HOPTON appointedSecretary
  7. Steven Charles Andrew HARRIS appointedDirector
  8. Cameron Robert MITCHELL appointedDirector
Earlier events (3)
  1. Graham Robert SMITH appointedDirector
  2. Christopher Blair WAGSTAFF appointedDirector
  3. Company incorporatedPrivate limited company

Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current persons with significant control, and the end of each financial year with figures in the database. Former persons with significant control are not listed.